ArticleLung Cancer (Auckland, N.Z.)2012

Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis.

V F Fragoulakis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.